Download PDF
Dtsch Med Wochenschr 2018; 113(13): 945-952
DOI: 10.1055/a-0538-3715
Dossier
© Georg Thieme Verlag KG Stuttgart · New York

Chronisch-entzündliche Darmerkrankungen: Diagnostik und Therapie in der Praxis

Inflammatory Bowel Diseases – Diagnosis and Therapy in Practice
Niels Teich
,
Tobias Klugmann
Further Information

Publication History

Publication Date:
04 July 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Significant increases in Crohn’s disease incidence have been noticed in recent decades. Therefore it gets more important to increase practical knowledge, present therapy innovations and draw attention to the need for vaccinations of immunosuppressed IBD patients as well as useful supportive therapy options.

Eine deutliche Inzidenzsteigerung in den letzten Jahrzehnten an chronisch-entzündlichen Darmerkrankungen (CED) Morbus Crohn und Colitis ulcerosa fordert besonders den haus- und fachärztlichen Bereich. Dieser Beitrag teilt praxisrelevantes Wissen, gibt Aussicht auf Neuerungen und weist auf erforderliche Impfungen immunsupprimierter CED-Patienten und Supportivtherapien hin.

Schlüsselwörter

Morbus Crohn - Colitis ulcerosa - Azathioprin - Impfung - Eisenmangel

Key words

Crohn’s disease - ulcerative colitis - azathioprine - vaccination - iron deficiency
 

  • Literatur

  • 1 Fumery M, Singh S, Dulai PS. et al. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol 2018; 16 (03) 343-356 . doi:10.1016/j.cgh.2017.06.016
    CrossrefPubMedGoogle Scholar
  • 2 Lee DW, Koo JS, Choe JW. et al. Diagnostic delay in inflammatory bowel disease increases the risk of intestinal surgery. World J Gastroenterol 2017; 23: 6474-6481 . doi:10.3748/wjg.v23.i35.6474
    CrossrefPubMedGoogle Scholar
  • 3 Preiß JC, Bokemeyer B, Buhr HJ. et al. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ 2014. Z Gastroenterol 2014; 52 (12) 1431-1484 . doi:10.1055/s-0034-1385199
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol 2014; 8: 197-210 . doi:10.1586/17474124.2014.869476
    CrossrefPubMedGoogle Scholar
  • 5 Falt P, Šmajstrla V, Fojtík P. et al. Carbon dioxide insufflation during colonoscopy in inflammatory bowel disease patients: a double-blind, randomized, single-center trial. Eur J Gastroenterol Hepatol 2017; 29: 355-359 . doi:10.1097/MEG.0000000000000791
    CrossrefPubMedGoogle Scholar
  • 6 Farnbacher M, Hohn H, Philipper M. Positionspapier Kapselendoskopie des bng. Zeitschrift für Gastroenterologie 2014; 52: 1-4
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Kucharzik T, Wittig BM, Helwig U. et al. Use of Intestinal Ultrasound to Monitor Crohn’s Disease Activity. Clin Gastroenterol Hepatol 2017; 15 (04) 535-542 . doi:10.1016/j.cgh.2016.10.040
    CrossrefPubMedGoogle Scholar
  • 8 Wenger S, Nikolaus S, Howaldt S. et al. Predictors for subsequent need for immunosuppressive therapy in early Crohn’s disease. J Crohns Colitis 2012; 6: 21-28 . doi:10.1016/j.crohns.2011.06.006
    CrossrefPubMedGoogle Scholar
  • 9 Caplan A, Fett N, Rosenbach M. et al. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Gastrointestinal and endocrinologic side effects. J Am Acad Dermatol 2017; 76: 11-16 . doi:10.1016/j.jaad.2016.02.1239
    CrossrefPubMedGoogle Scholar
  • 10 Teich N, Mohl W, Bokemeyer B. et al. Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity. J Crohns Colitis 2016; 10: 61-68 . doi:10.1093/ecco-jcc/jjv188
    CrossrefPubMedGoogle Scholar
  • 11 Coenen MJH, de Jong DJ, van Marrewijk CJ. et al. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. Gastroenterology 2015; 149: 907-917 . doi:10.1053/j.gastro.2015.06.002
    CrossrefPubMedGoogle Scholar
  • 12 Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opin Biol Ther 2016; 16: 1277-1290 . doi:10.1080/14712598.2016.1203897
    CrossrefPubMedGoogle Scholar
  • 13 Teich N, Klugmann T, Tiedemann A. et al. Vaccination coverage in immunosuppressed patients: results of a regional health services research study. Dtsch Arztebl Int 2011; 108: 105-111 . doi:10.3238/arztebl.2011.0105
    PubMedGoogle Scholar
  • 14 Kommission für Krankenhaushygiene und Infektionsprävention beim Robert Koch-Institut. Anforderungen an die Hygiene bei der medizinischen Versorgung von immunsupprimierten Patienten. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010; 53: 357-388 . doi:10.1007/s00103-010-1028-9
    CrossrefPubMedGoogle Scholar
  • 15 Rosenfeld G, Bressler B. The truth about cigarette smoking and the risk of inflammatory bowel disease. Am J Gastroenterol 2012; 107: 1407-1408 . doi:10.1038/ajg.2012.190
    CrossrefPubMedGoogle Scholar
  • 16 Cosnes J, Beaugerie L, Carbonnel F. et al. Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology 2001; 120: 1093-1099
    CrossrefPubMedGoogle Scholar
  • 17 Martin J, Radeke HH, Dignass A. et al. Current evaluation and management of anemia in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2017; 11: 19-32
    CrossrefPubMedGoogle Scholar
  • 18 Maconi G, Gridavilla D, Viganò C. et al. Perianal disease is associated with psychiatric co-morbidity in Crohn’s disease in remission. Int J Colorectal Dis 2014; 29: 1285-1290 . doi:10.1007/s00384-014-1935-6
    CrossrefPubMedGoogle Scholar